Bearish
This Biotech Stock Plunges 48%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’
Fulcrum Therapeutics' stock plummeted by 48% after the company announced it would discontinue pociredir, its lead drug candidate for sickle cell disea...